La economía de la I+D en la industria farmacéutica: un resumen

• Félix Lobo ^[1]
  1. [1] Universidad Carlos III de Madrid

     Universidad Carlos III de Madrid

     Madrid, España

     
• Localización: Papeles de economía española, ISSN 0210-9107, Nº 160, 2019 (Ejemplar dedicado a: Medicamentos, innovación tecnológica y economía), págs. 35-51
• Idioma: español
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    En este artículo resumimos las principales contribuciones que la economía industrial ha hecho al conocimiento de la naturaleza, características y evolución de la I+D farmacéutica. Repasaremos la división del trabajo entre sector público y sector privado y la relación entre I+D y riesgo. Después analizamos los incentivos que la impulsan, el patrón de la competencia entre las empresas innovadoras y las teorías que lo explican. La estructura cambiante de estas actividades, la eficiencia asignativa en sentido amplio, incluidos los costes que implican, su productividad y su rentabilidad se estudian sucesivamente. Acabamos discutiendo los factores determinantes de la I+D. Varios dilemas de las políticas industrial, tecnológica, de salud y desarrollo económico relacionadas con el sector farmacéutico pueden plantearse y resolverse mejor recurriendo a este cuerpo de conocimiento.

  • English

    This paper is a short review of the main contributions of Industrial Economics to improve our knowledge about the nature, characteristics and dynamics of pharmaceutical R&D. The overview first elucidates the public-private division of labour and the particular relation of pharma I+D with risk. The ultimate incentives driving I+D, the pattern of competition among innovative firms and the theories advanced to explain these patterns follow. Next points considered are the changing structure of pharma I+D, allocative efficiency comprising costs, productivity and returns. A discussion of the determinants driving R&D in this sector closes the overview. A number of dilemmas arising in industrial, technological, health, and development policies in the pharmaceutical sector are better understood ad solved relying on the stock and flow of knowledge provided by Industrial Economics.

• Referencias bibliográficas
  • aCemoglu, D. y linn, J. (2004). Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics,...
  • adams, C. P. y Van brantner, V. (2006). Estimating the Cost of New Drug Deve lopment : I s I t Rea l l y $802 Million? Health Affairs, 25(2),...
  • Banco Mundial GDP deflator: linked series https://data.worldbank.org/indicator/ NY.GDP.DEFL.ZS.AD
  • berndt, e. r., CoCkburn I. M. y grePin, K. A. (2006) The impact of incremental innovation in biopharmaceuticals. Drug utilisation in original...
  • blume-koHout, M. E. y sood, N. (2013). Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development....
  • CoCkburn, I. M. (2004). The changing structure of the pharmaceutical industry. Health Affairs, 23, pp. 10-22.
  • Cockburn, I. y Henderson, R. (1994). Racing to Invest? The Economics of Competition in Ethical Drug Discovery. Journal of Economics and Management...
  • Cockburn, I. y Henderson, R.— (1998). Absorptive Capacity, Co- Authoring Behavior, and the Organization of Research in Drug Discovery. Journal...
  • Cockburn, I. y Henderson, R.— (2001). Scale and Scope in Drug D e v e l o p m e n t : U n p a c k i n g t h e Advantages of Size in Pharmaceutical Research....
  • Comanor, W. S. (1964). Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States. Economica, 31, pp....
  • Comanor, W. S.— (1965). Research and Technical Change in the Pharmaceutical Industry. Review of Economics and Statistics. 47(2), pp. 182-190...
  • Comanor, W. S.— (2007). The economics of research and development in the pharmaceutical industry. En F. A. Sloan y C. H. Hsieh, Pharmaceutical...
  • Danzon, P. M y Nich olson, S. (eds.) (2012). The Oxford handbook of the Economics of the biopharmaceutical industry. New York: Oxford U.P....
  • Danzon, P., Nich olson, S. y Sousa Pereira, N. (2005). Productivity in pharmaceuticalbiotechnology R&D: The role of experience and alliances....
  • Del Llano Señarís (ed). (2017). Innovación y regulación en Biomedicina: obligados a entenderse. Madrid: Fundación Gaspar Casal, pp. 51-88....
  • Diario Médico (17 de diciembre de 2018).
  • DiMasi, J. A. y Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics, 28(4-5),...
  • DiMasi J. A. y Grabowski, H. G. (2012). R&D costs and returns to new drug development: a review of the evidence. En P. M. Danzon y S....
  • DiMasi, J. A., H. G. Grabowski y Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal...
  • DiMasi, J. A., Hansen, R. W. y Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of Health...
  • DiMasi, J. A., Hansen, R., Grabowski, H. G. y Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics,...
  • Dranove, D., Garthw aite, C. y Hermosilla, M. (2014). Pharmaceutical Profits and the Social Value of Innovation. Working Paper 20212. National...
  • Ev ens, R. P. (2016) Pharma success in produc t de v e lopmen t-Doe s Biotechnology change the paradigm in product development and attrition. AAPS...
  • García-Fontes, W. (ed.) (2011). Incentives for research, development, and innovation in pharmaceuticals. Edited by Vicente Ortún, CRES-UPF....
  • W. García-Fontes — (2011). Incentives for innovation a survey. En W. García-Fontes (ed.). Incentives for research, development, and innovation in...
  • Grabowski, H. G. (1968). The determinants of industrial research and development: A study of the chemical , drug, and petroleum industries....
  • Grabowski, H. G — ( 2 0 1 1 ) . T h e e v o l u t i o n o f t h e pharmaceutical industry over the past 50 years: a personal reflection....
  • Grabowski, H. G. y Vernon, J. (2000). The determinants of pharmaceutical research and development expenditures. Journal of Evolutionary Economics,...
  • Grabowski, H. G., Vernon, J. M. y DiMasi, J. A. (2002). Retuns on research and development for 1990s new drug introductions. PharmacoEconomics, 20(supl....
  • Hansen, R. W. (1979). The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory...
  • Harhoff, D. y Sch erer, F. M. (2000). Technology policy for a world of skew-distributed outcomes. Research Policy, 29, pp. 559- 566.
  • Harrington, S. E. (2012). Cost of capital for pharmaceutical, biotechnology, and medical device firms. En P. M. Danzon y S. Nich ol son (eds.),...
  • Hal l, B. y Rosenberg, N. (eds.) (2010). Handbook of the Economics of innovation. Amsterdam: North Holland.
  • Henderson, R. y Cockburn, I. (1996). Scale, scope, and spillovers: The determinants of research productivity in drug discovery.RAND Journal...
  • IMS institute for HealtHCare informatiCs. (2016). Delivering on the potential of biosimilar medicines The role of functioning competitive...
  • Jönsson, B. HofmarCHer , t. lindgren, P. y N. Wilking. 2016. Comparator report on patient access to cancer medicines in Europe Revisited....
  • kinCH, m. s., HaynesWortH, a., kinCH, S. L. y Hoyer, D. (2014). An overview of FDA-approved newmolecular entities: 1827-2013. Drug Discovery...
  • lakdaWalla, D. N. (2018). Economics of the Pharmaceutical Industry. Journal of Economic Literature, 56(2), pp. 397-449. https://doi.org/10.1257/jel.20161327
  • lakdaWalla, D. y sood, N. (2009). Innovation and the welfare effects of public drug insurance. Journal of Public Economics, 93(3-4), pp. 541-48....
  • lobo, F. (2017). Análisis y propuestas para hacer compatibles el fomento de la innovación y la disponibilidad de medicamentos. En del llano...
  • lobo, F. — (2019). La industr ia farmacéutica en la actualidad: un vistazo a sus características. Papeles de Economía Española, 160. Madrid:...
  • manski, C. F. (2009). Adaptive partial drug approval: A Health Policy proposal. The Economists’ Voice, 6(4). https:// www.degruyter.com/downloadpdf/j/...
  • mestre-ferrándiz, J., sussex, J. y toWse, A. (2012). The R&D cost of a new medicine. Office of Health Economics.
  • ministerio de sanidad, Consumo y bienestar soCial (2018). Nota informativa de la reunión de la Comisión Interministerial de Precios de los...
  • Morgan, S., Grootendorst, P., Lexch ine, J., Cunningham, C. y Greyson, D. (2011). The cost of drug development: A systematic review. Health...
  • OCDE (2017). Health at a glance. Paris:OCDE. https://doi.org/10.1787/health_glance-2017-en
  • Pr a s a d , V. y Ma i l ankod y , S. (2017). Research and development spending to bring a single cancer drug to market and revenues after...
  • Puig-Junoy, J. (2012a). La economía del sector biofarmacéutico: un panorama. En J. Puig-Junoy (ed.), Lecturas sobre economía del sector biofarmacéutico,...
  • Puig-Junoy, J. (ed.). (2012b). Lecturas sobre economía del sector biofarmacéutico. Madrid: Springer Healthcare. https:// axon.es/ficha/libros/9788494011849/ lecturas-sobre-economia-del-sectorbiofarmaceutico
  • Reinhardt, U. E. (2001). Perspectives on the pharmaceutical industry. Health Affairs. 20(5), pp. 136-49. https:// www.healthaffairs.org/doi/full/10.1377/ hlthaff.20.5.136
  • Rottingen, J. A., Regmi, S., Eide, M., Young, A. J., Viergever, R. F., Ardal, C., Guzman, J., Edwards, D., Matlin, S. A. y Terry, R. F. (2013)....
  • Scherer, F. M. (2001). The link between gross profitability and pharmaceutical R&D spending. Health Affairs, 20(5), pp. 216-220. https://www.healthaffairs.org/ doi/10.1377/hlthaff.20.5.216
  • Scherer, F. M.— (2010). Pharmaceutical innovation. En B. Hall y N. Rosenberg (eds.), 1, chap. 12.
  • Unión Europea (2000). Reglamento (ce) n.º 141/2000 del Parlamento Europeo y del Consejo de 16 de diciembre de 1999 sobre medicamentos huérfanos....
  • United States, Congress (1983). Public Law 97-414-Jan. 4, 1983. 97th Congress. An Act to amend the Federal Food, Drug, and Cosmetic Act to...
  • United States, Congress. Office of Tech nology Assessment (1993). Pharmaceutical R&D: costs, risks, and rewards. OTA-H-522. Washington...
  • United States, Food and Drug Administration (FDA ) , Cent e r for Drug Evaluat ion a n d Re s e a r ch (2018). Advancing health through innovation....
  • United States, Food and Drug Administration — (2019). Advancing health through i n n o v a t i o n . 2 0 1 8 n e w d r u g therapy approvals....
  • Ve rnon, J. A. (2005). Examining the link between price regulation and pharmaceutical R&D investment. Health Economics 14(1), pp. 1-16....
  • Vernon, J. M. y Gusen, P. (1974). Technical change and firm size: Pharmaceutical industry. Review of Economics and Statistics, 56, pp. 294–302....